|
pubmed:abstractText |
During the past decade, molecular signatures allowed a better classification of breast carcinoma and a better evaluation of their prognosis. However, we still need predictive factors of treatment and /or prognosis factors specific of each patient. Regarding hormonal therapy, expression of hormone receptors is essential, but not sufficient to accurately predict response to treatment for all patients. To date, numerous data have identified different pathways of resistance to hormonal treatment, associated with heterogeneity in response to long term treatment. The challenge remains to identify and to anticipate these changes for each patient.
|
|
pubmed:affiliation |
Institut Curie, Département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France. patricia.de-cremoux@curie.net
|
